机构名称：
¥ 1.0
Date Action January 2015 Addition to PA March 2015 Annual review and reference update June 2016 Annual editorial review and reference update Policy change from 5.04.52 to 5.21.52 June 2017 Annual editorial review and reference update Addition of unacceptable toxicity to renewal section September 2017 Annual review Addition of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer Addition of quantity limits Removal of no concurrent therapy with other治疗卵巢癌的药物2018年2月将转移性乳腺癌添加到启动和更新标准中。在新辅助，佐剂或转移性环境中添加BRCA阳性，先前的化学疗法治疗，如果先前必须对先前的内分泌治疗进行治疗，或者必须接受内分泌治疗的治疗，或者被认为是内分泌治疗的不适当候选者，用于内部分泌治疗，用于逐年诊断为672诊断672的培养基，以诊断为672的培训标准。新指示的添加：BRCA的晚期上皮卵巢，输卵管或原发性腹膜癌。Removal of Lynparza 50mg capsules March 2019 Annual review May 2019 Changed quantity limit to 360 tablets per 90 days for both strengths of Lynparza June 2019 Annual review January 2020 Addition of indication: metastatic pancreatic cancer March 2020 Annual review May 2020 Addition of indication: used in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube或原发性腹膜癌对一线铂化学疗法有完全或部分反应，其癌症为
lynparza（olaparib）
主要关键词
